These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 15645673)

  • 1. Qualification of virus/cell systems for their intended use.
    Gröner A
    Dev Biol (Basel); 2004; 118():55-63. PubMed ID: 15645673
    [No Abstract]   [Full Text] [Related]  

  • 2. EEC regulatory document. Note for guidance. Validation of virus removal and inactivation procedures. Committee for Proprietary Medicinal Products: Ad Hoc Working Party on Biotechnology/Pharmacy and Working Party on Safety Medicines.
    Biologicals; 1991 Jul; 19(3):247-51. PubMed ID: 1954007
    [No Abstract]   [Full Text] [Related]  

  • 3. Theoretical considerations on viral inactivation or elimination.
    Willkommen H; Löwer J
    Dev Biol Stand; 1993; 81():109-16. PubMed ID: 8174793
    [No Abstract]   [Full Text] [Related]  

  • 4. Virological issues in the use of cell therapies.
    Minor PD
    Dev Biol (Basel); 2004; 118():151-3. PubMed ID: 15645685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Animal virus contaminants of biotechnology products.
    Onions D
    Dev Biol (Basel); 2004; 118():155-63. PubMed ID: 15645686
    [No Abstract]   [Full Text] [Related]  

  • 6. Use of bacteriophages as surrogates for mammalian viruses.
    McAlister M; Aranha H; Larson R
    Dev Biol (Basel); 2004; 118():89-98. PubMed ID: 15645677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative NAT for pathogen inactivation verification.
    McKenney K; Gillmeister L; Marlowe K; Armistead D; Burgess W; Drohan W
    Dev Biol (Basel); 2004; 118():81-8. PubMed ID: 15645676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. European Regulatory guidance on virus safety of recombinant proteins, monoclonal antibodies and plasma derived medicinal products.
    Celis P; Silvester G
    Dev Biol (Basel); 2004; 118():3-10. PubMed ID: 15645667
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Issues related to harmonization of testing requirements for viral safety.
    Hayakawa T
    Dev Biol Stand; 1996; 88():15-8. PubMed ID: 9119129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Considerations in performing virus spiking experiments and process validation studies.
    Darling AJ
    Dev Biol Stand; 1993; 81():221-9. PubMed ID: 8174806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Methods for validation of hepatitis B virus inactivation.
    Gerlich WH; Glebe D
    Dev Biol (Basel); 2004; 118():113-22. PubMed ID: 15645680
    [No Abstract]   [Full Text] [Related]  

  • 12. Industry perspective for biotech products.
    Möritz A
    Dev Biol (Basel); 2004; 118():37-44. PubMed ID: 15645671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The clearance of viruses and transmissible spongiform encephalopathy agents from biologicals.
    Farshid M; Taffs RE; Scott D; Asher DM; Brorson K
    Curr Opin Biotechnol; 2005 Oct; 16(5):561-7. PubMed ID: 16095899
    [TBL] [Abstract][Full Text] [Related]  

  • 14. eSwab flocked swabs unfit for viral culture.
    Indevuyst C; Beuselinck K; Lagrou K
    J Clin Virol; 2012 Nov; 55(3):282-3. PubMed ID: 22858119
    [No Abstract]   [Full Text] [Related]  

  • 15. Viral safety of C1-inhibitor NF.
    Terpstra FG; Kleijn M; Koenderman AH; Over J; van Engelenburg FA; Schuitemaker H; van 't Wout AB
    Biologicals; 2007 Jun; 35(3):173-81. PubMed ID: 17071103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quality of biotechnological products: viral safety evaluation of biotechnology products derived from cell lines of human or animal origin. ICH Harmonised Tripartite Guideline.
    Dev Biol Stand; 1998; 93():177-201. PubMed ID: 9737396
    [No Abstract]   [Full Text] [Related]  

  • 17. Criteria for the choice of viruses in validation studies.
    Minor PD
    Dev Biol Stand; 1993; 81():215-9. PubMed ID: 8174805
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Introduction to the issues: new potential contaminants and other exogenous agents.
    Albrecht P
    Dev Biol Stand; 1992; 76():255-8. PubMed ID: 1478344
    [No Abstract]   [Full Text] [Related]  

  • 19. Minimum safety requirements for preclinical testing.
    Dorner F; Barrett PN; Schwartz HP; Eibl H
    Dev Biol Stand; 1993; 81():245-52. PubMed ID: 8174809
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current and future approaches to ensure the viral safety of biopharmaceuticals.
    Brorson K; Norling L; Hamilton E; Lute S; Lee K; Curtis S; Xu Y
    Dev Biol (Basel); 2004; 118():17-29. PubMed ID: 15645669
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.